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2Abstract
The abundance of long non-coding RNAs (lncRNAs) and their wide range of functional roles in 
human cells are fast becoming realized. Importantly, lncRNAs have been identified as epigenetic 
modulators and consequently play a pivotal role in the regulation of gene expression.  A human 
immunodeficiency virus (HIV) encoded antisense RNA transcript has recently been reported and 
we sought to characterize this RNA and determine its potential role in viral transcription 
regulation.  The intrinsic properties of this HIV-expressed lncRNA were characterized and the 
data presented here suggest that it functions as an epigenetic brake to modulate viral 
transcription. Suppression of this long antisense transcript with small single stranded antisense 
RNAs resulted in the activation of viral gene expression. This lncRNA was found to localize to 
the 5’LTR and to usurp components of endogenous cellular pathways that are involved in 
lncRNA directed epigenetic gene silencing. Collectively, we find that this viral expressed 
antisense lncRNA is involved in modulating HIV gene expression and that this regulatory effect 
is due to an alteration in the epigenetic landscape at the viral promoter. 
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3Introduction
Human Immunodeficiency Virus type 1 (HIV-1) is a lentivirus that causes a persistent infection, 
ultimately resulting in the demise of immune regulatory cells. In vivo, some HIV infections may 
undergo transcriptional shutdown leading to a state of viral latency in resting memory CD4+ 
cells (reviewed in [1]). The underlying cellular mechanism(s) responsible for establishing and/or 
maintaining latency remain indistinct [2]. It is known that the proviral genome functions 
analogously to host genes, interacting with chromosomal proteins and thus subject to the actions 
of the host epigenetic regulatory machinery (reviewed in [3]). Notably, the reactivation of latent 
virus has been shown to involve the acetylation of histone tails specifically at the HIV 
promoter/LTR. Conversely, silent state chromatin marks to the viral promoter/LTR have been 
observed when the provirus is repressed [4]. These insights suggest that epigenetic mechanisms 
are involved in viral latency. However, the mechanism by which these epigenetic marks are 
localized to particular targeted regions has remained unclear. 
The complex paradigm of RNA-based gene regulation is slowly being revealed and there is a 
large body of evidence that infers a central role for non-coding RNAs (ncRNAs) in controlling 
gene expression by targeting various stages of epigenetic remodeling (reviewed in [5]).  We and 
others have observed that antisense long non-coding RNAs (lncRNAs) are able to guide 
epigenetic silencing complexes to targeted loci in the promoters of protein coding genes resulting 
in gene silencing in human cells (reviewed in [6]). It is thus becoming apparent that antisense 
ncRNAs are endogenous effector molecules capable of utilizing RNA-based transcriptional 
silencing pathways in human cells [7-10]. This model lends itself to the possibility of disrupting 
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4RNAs, functional in both the transcriptional [11] and post-transcriptional gene silencing 
pathways [12, 13], can lead to suppression of the targeted lncRNA. This suppression results in
the de-repression of the lncRNA targeted protein-coding gene and ultimately the activation of 
that gene [7-10].
The number of functional lncRNAs being identified in human cells continues to rise and we are 
rapidly gaining an understanding of the disparate roles these transcripts play in different disease 
systems [14].  Antisense ncRNAs emanating from the HIV genome during viral infection have 
been described [15-18] and such transcripts are reportedly capable of suppressing HIV gene 
expression [17, 18]. As such we set out to further investigate the role of these HIV-encoded 
ncRNAs in the regulation of viral transcription and to gain insights into the mechanism by which 
this regulation occurs. We find here that the targeted suppression of HIV antisense ncRNAs by 
both post-transcriptional and transcriptional gene silencing of the ncRNA promoter can result in 
the activation of HIV gene expression and replication in both cell lines and primary human 
CD4+ T-cells.  Furthermore, we show that this ncRNA regulates viral gene expression by the 
endogenous RNA-directed epigenetic pathway involving DNA methyltransferase 3a (DNMT3a), 
histone deacetylase 1 (HDAC1), and the polycomb protein enhancer of zeste homolog 2 (EZH2).
Results
Characterization of HIV-expressed antisense ncRNAs
Several independent studies have observed an antisense transcript emanating from the nef region 
of HIV (Fig. 1a) [15, 16, 18]. In this study we sought to verify and further characterize this HIV-
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5investigated in the ACH2 and J1.1 cell lines, which are chronically infected cell lines harboring 
the HIV-1 LAI strain and have served as in vitro culture models for latent HIV-1 infection. The 
antisense ncRNA was detected by directional reverse transcription (RT) and PCR using various 
primers (annotated in Fig. 1a) and was clearly observed in both ACH2 (Fig. 1b) and J1.1 cells
(Fig. 1c). The detection of the ncRNA by directional RT was specific as evidenced by the failure 
to detect the ncRNA when using a PCR primer set upstream from the RT primer (Fig. 1d). The 
ncRNA transcript appears to span the majority of the viral genome (Fig. 1e), and overlaps the 
5’LTR (Fig. 1f). Previous studies have found that some antisense ncRNAs involved in 
epigenetically modulating gene transcription lack poly-adenylation [7]. We find that the HIV-
expressed antisense ncRNA characterized here also lacks a poly-adenylated tail (Fig. 1g), 
suggesting some level of nuclear retention [8] and correlates with previous reports that HIV-
expressed asRNAs are localized in the nuclei of infected cells [18]. Taken together, these data 
verify the existence of an HIV-encoded antisense lncRNA and the properties thereof are 
consistent with previous observations of endogenous ncRNAs in human cells [19, 20]. The 
possibility therefore exists that this HIV-expressed long antisense transcript may be involved in 
the epigenetic regulation of HIV.
Activation of HIV gene expression by suppression of the HIV-expressed antisense lncRNA
Elucidation of the role of this HIV-encoded ncRNA and the molecular mechanism by which it 
acts could provide invaluable insight into a potential contributing component of viral latency.  It 
has previously been reported that suppression of certain ncRNAs by RNA interference, either in 
vitro or in vivo, has resulted in de-repression of the ncRNA targeted protein-coding gene and 
concomitant transcriptional activation [7-9, 12]. Similarly, we show that suppression of this HIV 
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6small single stranded antisense RNA targeted to the HIV-encoded antisense non-coding RNA 
transcript at the region overlapping the env gene (as154) (Fig. 2a) was cloned into an HIV-1 
lentiviral vector (HIV7) containing the MPA selectable IMPDH2 gene (Fig. 2b). Activation of 
HIV gene expression and replication is shown in HIV-infected primary CD4+ T cells stably-
transduced with a lentiviral vector expressing the U6-driven as154 small RNA and is shown by 
qPCR (Fig. 2c) and p24 antigen ELISA (Fig. 2d).  This activation correlates with a concomitant 
reduction of the HIV-expressed antisense lncRNA caused by post-transcriptional gene silencing 
(Fig. 2e).  Nuclear run on assays show that the observed activation of HIV is transcriptional in 
nature (Fig. 2f). These data showing knockdown of the HIV lncRNA and the consequent 
activation of HIV, suggest that the HIV antisense lncRNA plays a role in regulating HIV gene 
expression and replication. To determine possible changes in histone modifications in cells 
where the antisense lncRNA has been manipulated, ChIP analysis was performed at the viral 
5’LTR using antibodies against the silent state histone modifications H3K27me3 and H3K9me2
(Figs. 2g,h).  In stable ACH2 cells expressing the small RNA as154 in which the HIV antisense 
lncRNA is downregulated, we observed a reduction in both H3K27me3 (Fig. 2g) and H3K9me2
(Fig. 2h) at the viral promoter.  The HIV antisense lncRNA therefore appears to be responsible 
for regulating the epigenetic state at the viral promoter and subsequent viral gene transcription, 
similar to previous observations with endogenous lncRNAs [8].
Susceptibility of HIV-expressed antisense ncRNA to transcriptional gene silencing
Next, we sought to determine the susceptibility of the HIV-encoded antisense lncRNA to 
silencing with small RNAs utilizing the transcriptional gene-silencing pathway. Target sites 
within the previously characterized promoter [15] driving the HIV antisense lncRNA were 
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7targeting the identified regions within the promoter (aspro1-5) (Fig. 3a) were cloned into 
lentiviral vectors (Fig. 3b), stable cell cultures were generated, and their resulting activating 
properties determined.
We find that the targeted suppression of this HIV expressed ncRNA with small RNAs utilizing 
the transcriptional silencing pathway also results in the activation of HIV expression (Figs. 3c,d).   
Three of the small antisense RNAs (asRNAs) caused activation of viral gene expression in stable 
J1.1 cell populations expressing the asRNAs (Fig. 3c) and nuclear run on assays showed that the 
observed activation was at a transcriptional level (Fig. 3d). One small asRNA targeted to the 
reported promoter for the HIV-expressed antisense ncRNA, aspro5, proved consistently effective 
at activating HIV expression across different cell lines. In addition, the level of activation by the 
aspro5 small asRNA was found to be at a similar level to that of a post-transcriptionally targeted 
small RNA, the as154 (Figs. 2c,d). A lentiviral vector expressing the aspro5 small asRNA (Fig. 
3b) was then used to transduce primary CD4+ T cells. When these cells were infected with HIV
those cultures stably expressing small asRNA aspro5 exhibited signficant viral activation relative 
to their control counterpart (Fig. 3e). The aspro5-induced HIV activation correlated with the 
specific knockdown of the HIV antisense lncRNA in a dose dependent manner in cells co-
transfected with a plasmid expressing the HIV lncRNA and a plasmid expressing aspro5 (Fig. 
3f). These data suggest that the observed activation of viral gene expression is a consequence of 
aspro5-mediated inhibition of the HIV-expressed antisense lncRNA. To determine the effect of 
the small RNA aspro5 mediated inhibition of the HIV antisense lncRNA on the chromatin state 
at the viral promoter, ChIP analysis was performed at the 5’LTR (Fig. 3g).  In cells transduced 
with a lentiviral vector expressing aspro5, we observed a marked reduction in silent state histone 
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83g). Collectively, the observations presented in (Figs. 2 and 3) suggest that this HIV encoded 
lncRNA is involved in the epigenetic regulation of viral transcription.
Epigenetic-based mechanism of lncRNA-mediated HIV transcriptional regulation
To exclude the possibility of non-specific gene knockdown effects or toxicities caused by the 
induction of a non-specific interferon response following introduction of small activating RNAs
into the cellular environment, IFN-β mRNA concentrations were measured in cells expressing 
as154 or aspro5 and in those cells treated with the dsRNA analogue poly (I:C).  However, neither 
small RNA treated cell was observed to induce expression of IFN-β (Fig. 4a).  Endogenous 
mechanisms of ncRNA-based transcriptional regulation in human cells utilize various 
components of the epigenetic regulatory pathway. Recent findings have demonstrated that DNA 
methyltransferase 3A (DNMT3a) plays a pivotal role in this pathway through direct interactions 
with ncRNAs [8]. Mechanistically ncRNAs are thought to direct DNMT3a and other proteins 
which form part of an epigenetic remodeling complex, to target loci ultimately resulting in stable 
epigenetic based silencing of the ncRNA targeted locus (reviewed in [21]). To determine 
whether the HIV antisense lncRNA described here directly interacts with DNMT3a, directional 
qRTPCR was performed on eluates from a DNMT3a immunoprecipitation (ChIP) for detection 
of the antisense ncRNA. We find here that the HIV antisense lncRNA associates with DNMT3a 
in both ACH2 and J1.1 cells (only Ach2 cells shown, Fig. 4b). To determine whether this HIV-
expressed lncRNA localizes to the HIV promoter, two synthetic biotinylated fragments of the 
HIV antisense lncRNA transcript, each 1000 bp in length were generated by T7 transcription and 
transfected into ACH2 cells. One of these fragments (HIV asRNA LTR-gag) represented the 3’
end of the antisense lncRNA overlapping the 5’LTR region and the other fragment (HIV asRNA 
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9the biotinylated transcripts was performed 30 hours post-transfection and qPCR showed that the 
synthetic HIV antisense ncRNA fragment, representing the 3’ end of the endogenous antisense 
lncRNA, localized directly to the 5’LTR (Fig. 4c). After independently showing that the HIV 
lncRNA interacts directly with DNMT3a (Fig. 4b) and localizes to the 5’LTR (Fig. 4c), we 
looked at the localization of both entities in a DNMT3a-ncRNA complex. Immunoprecipitation 
of DNMT3a followed by a biotin pull-down in cells transfected with synthetic biotinylated HIV
antisense ncRNA transcripts revealed that the HIV lncRNA co-immunoprecipitated with 
DNMT3a specifically at the 5’LTR (Fig. 4d) and were found by mass-spec analysis to be in 
complex with various histones and known lncRNA binding proteins, such as Nucleolin (Table 1)
[7]. These observations suggest that the HIV antisense lncRNA is directly involved in localizing 
DNMT3a to the 5’LTR, leading to transcriptional regulation of the provirus, as has been 
observed previously with both genes and pseudogenes in human cells [8, 10]. Furthermore, 
ChIP analysis showed that the localization of DNMT3a to the HIV 5’LTR was diminished in 
ACH2 cells stably expressing the as154 or aspro5 small RNAs relative to an empty vector 
control (Fig. 4e). 
In addition to DNMT3a, the role of other chromatin modifying proteins such as the polycomb 
protein enhancer of zeste 2 (EZH2) and histone deacetylase 1 (HDAC1) were investigated for 
their possible role in the HIV antisense lncRNA mediated transcription regulation.  ChIP analysis 
was performed at the 5’LTR of chronically infected ACH2 cells transduced with lentiviral 
vectors expressing the small inhibitory RNAs as154 or aspro5 (Figs. 4f,g).  A reduction in both 
EZH2 (Fig. 4f) and HDAC1 (Fig. 4g) was observed at the viral promoter in cells in which the 
lncRNA had been manipulated by as154 or aspro5 when compared to cells transduced with an 
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10
and guiding a chromatin-remodeling complex consisting of proteins such as DNMT3a, EZH2 
and HDAC1 to the viral promoter.  The presence of these proteins at the 5’LTR leads to changes 
in histone modifications and an altered chromatin state at the viral promoter resulting in reduced 
levels of viral gene expression.
Collectively, these data suggest that the HIV expressed antisense lncRNA is involved in 
transcriptionally modulating expression of the virus, presumably through epigenetic mediated 
mechanisms in the human cell, and that this pathway is susceptible to the regulatory effects of 
aspro5. To determine whether the aspro5 small asRNA is also acting via an epigenetic based 
mechanism at the putative promoter of the HIV antisense lncRNA, cells stably expressing aspro5 
were infected with either the CCR5 receptor tropic (HX10) or CXCR4 receptor tropic (NL4-3)
HIV variants and subsequently treated with a combination of 5-Azacytidine (5-AC) and
Trichostatin A (TSA). These compounds inhibit DNA methyltransferases and histone 
deacetylases respectively and hence actively suppress RNA directed epigenetic mediated gene 
silencing in human cells [22, 23]. The activating effect of the aspro5 in stably transduced cells 
expressing aspro5 and infected with HIV was reversed by treatment with 5-AC and TSA (Fig. 
4h), suggesting that aspro5 suppresses the expression of the HIV antisense lncRNA via an 
epigenetic-based mechanism. 
Effects of aspro5 on viral latency
Several epigenetic marks have been associated with viral latency and we have shown that the 
HIV expressed antisense lncRNA characterized above regulates HIV expression by an 
epigenetic-based mechanism. We therefore investigated the effects of aspro5-mediated 
repression of the HIV-encoded lncRNA on viral latency in an ex vivo memory CD4+ T cell-
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11
from a healthy donor and activated in non-polarizing conditions for 3 days. At day 4 post-
activation, cells were transduced with a control or aspro5-expressing lentiviral vector (Fig. 3b) 
and kept in culture in the presence of IL-2. At day 5 post-activation cells were infected with the 
replication-deficient HIV-1 NL4-3 (DHIV) and productive infection was monitored by analysis 
of GFP and p24 by flow cytometry at different time points. Marginal viral activation was 
observed at day 12 (Fig. 5).  Previous observations have demonstrated a requirement for active 
transcription in the initial establishment of ncRNA-directed gene silencing [27, 28]. Consistent 
with this mechanism, the activation of HIV mediated by the aspro5 appeared to require 
replication-competent virus, as replication-defective, stably integrated variants in the resting 
memory CD4+ T-cell model were relatively resistant to this form of activation [24, 25] (Fig. 5).
Discussion
Recent advances in transcriptomic studies have revealed that a much larger fraction of the human 
genome is transcribed in both the sense and antisense directions than was previously envisioned 
[29-31]. Examples of bidirectional transcription have demonstrated a role for these ncRNAs in 
the epigenetic regulation of gene expression [7, 9, 10, 32, 33]. Here we extend these observations 
to HIV and define a function for HIV-expressed antisense transcripts. The data presented here, 
along with previous observations [15, 16, 18], suggest that HIV expresses an endogenous 
antisense ncRNA that appears to be functional in the transcriptional and epigenetic regulation of 
the virus (Fig. 6). 
Non-coding RNAs have been shown to guide epigenetic complexes to targeted gene promoters 
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12
coding RNAs antisense to low-copy promoter-associated RNA are able to direct transcriptional 
silencing complexes containing HDAC-1, Ago-1 and DNMT3a to a targeted promoter leading to 
histone modifications and heterochromatin formation [10, 27, 34-38].  These observations 
suggest that antisense ncRNAs are actively involved in the epigenetic regulation of gene 
expression.  The evidence presented here and in previously published studies indicates that HIV-
1 expresses a long ncRNA in the antisense orientation to the viral LTR and viral mRNA [15, 16, 
39].  Small RNAs targeting non-coding regions have previously been shown to induce epigenetic 
activation by targeting antisense lncRNAs [9, 11, 40, 41].   The data presented here demonstrate 
that HIV activation can be mediated by small RNAs targeted to the HIV-encoded antisense long 
ncRNA.  Furthermore, we have shown that the localization of both DNMT3a and HDAC1 to the 
viral LTR is reduced upon small RNA-mediated viral activation and in addition, we observe a 
loss of silent state histone modifications at the viral promoter when the HIV antisense lncRNA is 
inhibited.  It is therefore likely that this viral-encoded lncRNA may guide epigenetic silencing 
complexes to the LTR and induce transcriptional shutdown. It appears therefore likely that HIV 
gene expression and replication may be regulated by a similar system to those endogenous 
cellular genes under antisense ncRNA directed gene regulation and may also utilize a DNMT3a-
mediated mechanism of action (reviewed in [21]).
How and when HIV latency emerges has remained enigmatic but the process by which the virus 
undergoes latency appears to clearly involve epigenetic-based silencing mechanism [4]. The 
activation of latent virus has been well characterized and requires the recruitment of histone 
acetyltransferases as well as other chromatin remodeling proteins to the activated viral 
promoter/LTR [42, 43].  Conversely, enrichment of silent state chromatin marks (such as histone 
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13
inactive proviruses [44-47]. These reports suggest a distinct role for chromatin remodeling, and 
thus the host epigenetic response, in viral latency. However the endogenous factors responsible 
for guiding host epigenetic complexes to specific loci are currently unknown.  Here we provide 
evidence of an HIV-encoded lncRNA that appears to regulate viral gene expression by inducing 
changes in chromatin structure at the LTR.  It thus remains a possibility that this viral lncRNA 
may play a role in directing and guiding the establishment and/or maintenance of latency.
An alternative notion is that the HIV-expressed antisense transcript may align with a common 
theme of human cell specific integrating viral elements. Pseudogenes, some of which are 
essentially prehistoric viral entities, express antisense ncRNAs that are functional in the 
epigenetic regulation of gene expression [7] and also function in a DNMT3a dependent manner 
[8]. One similarity between HIV and endogenous pseudogenes is that both entities exhibit 
bidirectional transcription from their respective promoter elements. This suggests that these 
elements are important for epigenetic-based gene regulation, a concept that is supported by the 
observed action of aspro5 presented here (Fig. 6).
While the essence of the endogenous mechanism by which HIV enters a state of latency remains 
to be fully determined, the data presented here suggests one mechanism by which HIV 
epigenetically regulates its own gene expression. We present here the possibility that the HIV-
expressed antisense transcript is involved in the transcriptional shut down of the virus and that 
the inhibition of this transcript may lead to the activation of viral replication.  An understanding 
of this underappreciated role for HIV-expressed antisense non-coding RNAs in the HIV viral 
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Cell culture and viral infections
HEK293T cells were maintained in DMEM (Mediatech, VA, USA) supplemented with 10% 
fetal bovine serum (FBS) (Life Technologies, CA, USA) and 50ug/ml Pen/Strep (Mediatech, 
VA, USA) at 37°C and 5% CO2.   ACH2 and J1.1 cells are chronically infected cell lines 
harboring the HIV-1 LAI strain. ACH2, J1.1 and the J1.1 parental Jurkat cell lines were 
maintained in RPMI 1640 (Mediatech, VA, USA) supplemented with 10% FBS and 50 ug/ml 
Pen/Strep at 37°C and 5% CO2. Primary CD4+ T cells were maintained in RPMI 1640 
supplemented with 10% heat-inactivated FBS, 50 ug/ml Pen/Strep, and 30 U/ml human rIL-2. 
Isolated CD4+ T cells were stimulated with anti-CD3/CD28 Dynabeads (Life Technologies, CA, 
USA).  Cells were infected with the HIV-1 strains HX10 or NL4-3 at an MOI of 0.1.
Lentiviral vectors and flow cytometry
Lentiviral vectors were produced by co-transfection of 10 µg of pRRE-GAG/Pol, 2.5 µg of 
pRSV-Rev, 5 µg of pMD2.G VSV-G, and 15 µg of the various HIV7-IGFP vectors into HEK 
293T cells using calcium phosphate. High titer lentiviral vector stocks were prepared by
ultracentrifugation on a 20% sucrose gradient in a SW32 Ti rotor (Beckman Coulter, CA, USA) 
for 2 hours and 20 minutes at 19,400 rpm. The vectors were titered on HEK293T cells and 
analyzed for green fluorescent protein (GFP) expression by flow cytometry (FACSCalibur II, 
Becton, Dickinson and Company, NJ, USA) to determine infectious particles (IP) per milliliter.  
Jurkat, ACH2 and J1.1 cells were transduced at a multiplicity of infection (MOI) of 1 IP/cell by 
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IP/cell.  Cells were placed under 2 µM mycophenolic acid (MPA) (Sigma-Aldrich, MO, USA) 
selection 72 hrs post transduction for 8 days, after which enrichment of GFP-positive cells was 
confirmed by flow cytometry.  Cells were collected and fixed in 1% formaldehyde post staining 
for all experiments. CD4 was stained using anti-CD4-APC (MHCD0405; Life Technologies, 
CA, USA). Stained/GFP-positive cells were analyzed using a BD FACSCalibur II.
RNA isolation and analysis
Total cellular RNA was isolated according to the manufacturer’s instructions using the RNeasy 
Mini kit (QIAGEN, CA, USA). RNA samples were DNase-treated using the Turbo DNA-free™ 
Kit (Life Technologies, CA, USA) according to the manufacturer’s instructions. DNase-treated 
RNA samples were then standardized and reverse transcribed with Mu-MLV (Life Technologies, 
CA, USA) according to the manufacturer’s instructions using a gene specific primer or an oligo-
dT/random nonamer primer mix. The following gene specific primers were used:  RT primer 1: 
5ʹ-cctagtataaacaatgagacaccaggg-3’; RT primer 2:  5ʹ-cactcccaacgaagacaagata-3’; RT primer 3: 5ʹ-
ccctgtgagcctgcatggaatggatgaccc-3’; RT primer 4: 5ʹ-actgctgacatcgagcttgctaca-3’.  PCR was 
carried out using Kapa2G Fast HotStart ReadyMix according to the manufacturer’s instructions.  
The following PCR primers were used:  Primer set 1 F: 5ʹ-tgagacaacatctgttgaggtggg-3’; Primer 
set 1 R: 5ʹ-ggctgtactgtccatttatcagga-3’; Primer set 2 F: 5ʹ-ttgttctgctgctgcacta-3’; Primer set 2 R: 
5ʹ-agctatgttccttgggttct-3’; Primer set 3 F: 5ʹ-ctttccgctggggactttccagg-3’; Primer set 3 R: 5ʹ-
ccagagagacccagtacaggcaaaaagcag-3’; Primer set 4 F: 5ʹ-ctttccgctggggactttccagg-3’; Primer set 4 
R: 5ʹ-ttcgctttcaggtccctgt-3’.  Quantitative real-time PCR (qRT-PCR) was carried out using Kapa 
Sybr Fast universal qPCR mix (Kapa Biosystems, MA, USA) according to the manufacturer’s 
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min at 95°C, followed by 40 cycles of 95°C for 3 sec and 60°C for 30 sec. Specificity of the PCR 
products was verified by melting curve analysis.  The following primers were used for qPCR:  
Primer set 5 F: 5ʹ-agggatggaaaggatcaccagcaa-3’; Primer set 5 R: 5ʹ-cccacctcaacagatgttgtctca-3’; 
β-actin F: 5ʹ-aggtcatcaccattggcaatgag-3’; β-actin R: 5ʹ-tctttgcggatgtccacgtca-3’.  To determine 
induction of a non-specific immune response, RNA was collected as described above 24 hours 
following treatment with 10ug/ml poly(I:C) (Sigma, MO, USA) and IFN-β induction was 
determined by qRT-PCR using the IFN-β specific primers: IFN-β F: 5ʹ-tccaaattgctctcctgttgtgct-
3’ and IFN-β R: 5ʹ-ccacaggagcttctgacactgaaaa-3’.
p24 analysis
Samples were neutralized by lysis in Triton X-100 at a final concentration of 0.5%. Viral p24 
analysis was performed by the Translational Virology Core at the University of California San 
Diego Center for AIDS Research using the PerkinElmer Extended Curve p24 ELISA assay.
Immunoprecipitation analysis
Chromatin immunoprecipitation (ChIP) analyses and RNA immunoprecipitation (RNA-IP) 
analyses were performed by standard protocols adapted for automation using the epMotion 5070 
automated pipetting system (Eppendorf, Germany).  ChIP eluates were purified using the 
MinElute PCR purification kit (QIAGEN, CA, USA) and analyzed by qPCR.  RNA-IP eluates 
were not treated with RNaseA.  Eluates were DNase-treated, purified with acid 
phenol:chloroform (Life Technologies, CA, USA) and analyzed by directional RT and qPCR.  
Directional RT primer sequences are listed in the RNA isolation and analysis methods section 
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ctttccgctggggactttccagg-3’; Primer set 3 R: 5ʹ-ccagagagacccagtacaggcaaaaagcag-3’.  To 
determine non-specific induction of the immune response 
Biotin pull-down assay
Fragments of the HIV antisense lncRNA approximately 1000 bp long were generated by T7 
transcription using the Ampliscribe™ T7-Flash™ Biotin –RNA Transcription Kit (Epicentre® 
Biotechnologies, WI, USA) according to the manufacturer’s instruction.  Templates for T7 
transcription was prepared by PCR of pNL4-3 using primers: T7asHIV5ʹLTR F: 5ʹ-
cagtgaattgtaatacgactcactatagggtcctgtctgaag-3’ and asHIV5ʹLTR R: 5ʹ-
tggaagggctaatttggtcccaaaaaagac-3’ or PCR of pME18S-asHIV [18] using primers: T7asHIV F: 
5ʹ-cagtgaattgtaatacgactcactatagggttctttgggagt-3’ and asHIV R: 5ʹ-gaataacatgacctggatggagtggga-
3’.  Two fragments of the antisense lncRNA were generated, one fragment overlapping the 
5’LTR and one fragment overlapping a region in the nef gene.  Transcripts were transfected into 
ACH2 cells at a concentration of 50nM using the NEON® Transfection System (Life 
Technologies, CA, USA).  30 hours post transfection, cells were cross-linked with formaldehyde 
at 1% for 10 minutes at room temperature followed by addition of glycine to a final 
concentration of 0.125M and a further incubation for 5 minutes at room temperature.  Cells were 
then washed with PBS supplemented with PMSF, aproteinin and leupeptin and lysed with ChIP 
lysis buffer (50 mM Hepes, 140 mM NaCl, 1% Triton X, 0.1% NAD) on ice for 20 minutes.  
Chromatin was sheared by sonication.  Cell lysates containing sheared chromatin, or ChIP 
eluates in the case of ChIP-biotin dual pull-down assays, were incubated with Dynabeads® 
MyOne™ Streptavidin C1 (Life Technologies, CA, USA) prepared according to the 
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magnet for 3 minutes and washed with Low salt immune complex wash buffer (0.1% SDS; 1% 
Triton X-100; 2 mM EDTA; 20 mM Tris-HCl, pH 8.1; 150 mM NaCl); High salt immune 
complex wash buffer (0.1% SDS; 1% Triton X-100; 2 mM EDTA; 20 mM Tris-HCl, pH 8.1; 
500 mM NaCl); LiCl Immune complex wash buffer (0.25 M LiCl; 1% NP40; 1% sodium 
deoxycholate; 1 mM EDTA; 10 mM Tris-HCl, pH 8.1); and TE buffer (10 mM Tris-HCl; 1 mM 
EDTA, pH 8.0).  Each wash step was carried out for 3 minutes on a rotating platform.  
Streptavidin bead-biotinylated RNA-DNA complexes were re-suspended in elution buffer 
(10mM Tris-HCl, pH 6.0; 1mM EDTA; and 2 M NaCl) and heated at 70°C for 10 minutes. The 
supernatants were used for mass spec. The triplicate sample elutes were then pooled together, 
speedvac’d, and subjected to LC/MS at UNSW Australia (BMSF Core facility, UNSW).  
Electrospray tandem mass spectrometry
Mass Spectrometry was performed with the LTQ Fourier transform ion cyclotron resistance and 
the LTQ Orbitrap mass spectrometer (Thermo Fisher Scientific, Waltham, MA). Peak lists were 
generated using Mascot Daemon/extract_msn (Matrix Science, London, England, Thermo) using 
the default parameters, and submitted to the database search program Mascot (Matrix Science, 
London, UK; version 2.3.02) (Perkins, D et al Electrophoresis 1999:20:3551-3567). Mascot was 
set up to search the Swiss-Prot database version_25_10_13 comprising 541561 total entries 
(20352 entries following taxonomy filter). Mascot was searched with taxonomy set to Homo 
sapiens, a peptide mass tolerance 4 ppm and fragment ion mass tolerance ± 0.4 Da. Oxidation of 
methionine and carbamidomethyl of cysteine were specified in Mascot as variable 
modifications. The enzyme specificity was set to trypsin with allowance for up to 1 missed 
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Criteria for protein identification: Scaffold (version Scaffold_4.2.1, Proteome Software Inc., 
Portland, OR) was used to validate MS/MS based peptide and protein identifications. Peptide 
identifications were accepted if they could be established at greater than 95.0% probability by
the Peptide Prophet algorithm [48] with Scaffold delta-mass correction. Protein identifications 
were accepted if they could be established at greater than 99.9% probability and contained at 
least 2 identified peptides. Protein probabilities were assigned by the Protein Prophet algorithm 
[49]. Proteins that contained similar peptides and could not be differentiated based on MS/MS 
analysis alone were grouped to satisfy the principles of parsimony. Proteins sharing significant 
peptide evidence were grouped into clusters. Proteins were annotated with GO terms from NCBI 
(downloaded 19/12/2013)[50]. Those protein candidates from the anti-DNMT3a-asHIV IP were 
contrasted with control anti-DNMT3a-Lambda and no antibody-Lambda IPs. The top candidates 
not found in  the controls are shown with the number of different peptide reads and percent 
coverge (Table 1).
Nuclear run-on assays
Approximately 4e6 cells were lysed with NP-40 lysis buffer (10 mM Tris-HCl; 10 mM NaCl; 3 
mM MgCl2; 0.5% NP-40). Nuclear lysates were incubated with transcription buffer (10mM Tris-
HCl, pH 8.0; 2.5 mM MgCl2; 150 mM KCl; 2 mM DTT supplemented with 2 mM ATP, CTP 
and GTP; 1 mM Biotin-16-AA-5ʹ-UTP and 100 U RNase OUT) for 30 minutes at 37°C.  
Samples were Dnase-treated (Turbo DNase, Life Technologies, CA, USA) and then incubated 
with nuclei lysis buffer (50 mM Tris-HCl, pH 7.4; 5% SDS; 0.125 M EDTA) and proteinase K at 
37°C for 30 minutes.  Transcribed RNA was purified by acid-phenol:chloroform extraction. 
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Streptavidin C1 (Life Technologies, CA, USA) prepared according the manufacturer’s 
instruction. Captured RNA was washed 3 times with Bind/Wash Buffer (5 mM Tris-HCl, pH7.4; 
0.5 mM EDTA; 1 mM NaCl) and analyzed by qRT-PCR.
5-Azacytidine and Trichostatin A treatment
Various vector stable transduced Jurkat cell lines were treated with 4 uM 5-AC and 0.5 uM TSA 
for 72 hours before analysis.  Fresh 5-AC was added to the cells every 24 hours
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Figure 1 Characterization of HIV-1 expressed antisense ncRNAs. (a) Schematic representation 
of the HIV-1 genome. The 5’LTR promoter is highlighted depicting the binding sites of the 
various directional RT (depicted by green arrows) and PCR (depicted by red arrows) primers 
used to detect the HIV-1 antisense ncRNA. (b) Detection of the HIV-1 antisense ncRNA in 
ACH2 cells. (c) Detection of the HIV-1 antisense ncRNA in J1.1 cells. The ncRNA was detected 
in (B) and (C) using directional RT primer 1 and the pol specific PCR primer set 1.  The HX10 
molecular clone plasmid was used as a positive PCR control. (d) Specificity of ncRNA detection. 
The antisense ncRNA is undetectable with PCR primer set 4, which is upstream of the RT primer
1 site. (e) The antisense ncRNA spans the majority of the HIV genome.  The HIV-encoded 
antisense ncRNA detected spans env, pol and part of gag, significantly beyond the previously 
proposed antisense polyA signal [16] as determined by RT with the gag specific RT primer 1 and 
PCR with the env specific primer set 2. (f) The HIV-encoded antisense ncRNA overlaps the 
5’LTR. This panel shows detection of LTR overlapping antisense transcripts in ACH2 cells as 
determined by directional reverse transcription and PCR with the primers shown schematically. 
(g) The antisense ncRNA lacks a poly A tail.  Directional RT was performed with the following 
primers: forward primer of primer set 3 (set 3 F) found within the LTR, a control oligo (dT) 
primer (dTT), and a combination of both set 3 F and dTT (mix), using total RNA or dTT cleared 
RNA as a template.  The ncRNA-specific RT primer was able to detect a product from the total 
and dTT-cleared RNA samples whereas the oligo (dT) control primer was only able to detect a 
primer in the total RNA as expected.  This is consistent with previously published data showing 
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Figure 2 The effects of a stably expressed antisense RNA targeted to the HIV-1-expressed 
antisense transcript on viral gene expression. (a) Schematic representation of the small antisense 
RNA (as154) target site within the HIV-1 expressed ncRNA transcript. (b) HIV-1 lentiviral 
vectors containing the MPA selectable IMPDH2 gene used to transduce and generate stable cell 
lines containing integrated vectors. The control vector is an empty HIV-1 lentiviral vector and 
the HIVas154 vector contains the activating U6-as154 expression cassette. (c,d) CD4+ T-cells 
were transduced with the respective vectors (MOI=20) and stable cells were infected with HIV-1
HX10 (MOI=0.1). The cultures were assessed 72 hrs later by (c) qRTPCR for viral expression 
and (d) by p24 antigen ELISA. (e) The HIV-1 antisense RNA expression was characterized by 
directional RT and qPCR in the small RNA transduced CD4+ T-cells as described in Figs. 2b,c. 
(f) Nuclear run-on analysis of the transduced HIV-1-infected CD4+ T-cells. For (Figs. 2c,e,f,)
HIV gene expressing was measured by qPCR with primer set 5 within the RT region.  For (Figs.
2c-f) triplicate treated cultures are shown as mean + SD and p-values from a paired T-test. (g) 
ChIP analysis was performed to determine changes in histone modifications at the 5’LTR in cells 
expressing the small RNA as154. A reduction of H3K27me3 at the 5’LTR was observed in 
ACH2 cells transduced with a lentiviral vector expressing as154.  (h) ChIP analysis also revealed 
a reduction of H3K9me2 at the viral 5’LTR in ACH2 cells transduced with a lentiviral vector 
expression as154. For (Figs. 2g,h) enrichment at the 5’LTR was determined by qPCR with 
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Figure 3 Transcriptional activation of HIV-1 by small antisense RNAs targeting of the asHIV
promoter. (a) Schematic representation of the small antisense RNA target sites in the HIV-1 
expressed ncRNA promoter [16]. (b) HIV-1 lentiviral vectors containing the MPA selectable 
IMPDH2 gene used to transduce and generate stable cell lines containing integrated vectors. The 
control vector is an empty HIV-1 lentiviral vector and the HIVaspro vectors contain the U6-
driven small RNAs targeted to the HIV-1 expressed ncRNA promoter, aspro1-5. (c) The effects 
of small antisense RNA promoter targeting on viral gene expression in vector transduced stable 
pools of J1.1 cells. (d) Activation of HIV-1 gene expression from nuclear run on analysis in 
transduced J1.1 cells stably expressing small ncRNAs targeted to the asHIV promoter. (e) The 
effects of small RNA aspro5 on viral gene expression in primary CD4+ T cells.  Stably 
transduced aspro5-expressing CD4+ T cells were infected with HIV-1 NL4-3 (MOI=0.1) and 
viral expression determined 72hrs later. (f) Specific inhibition of the HIV antisense ncRNA by 
small RNA aspro5. Transient co-transfection of cells with pME18S-asHIV [18] expressing the 
full length HIV-1 antisense ncRNA and pU6M2-aspro5 shows that aspro5 knocks down the 
antisense ncRNA in a dose dependent manner. (Figs. 3c,d) represent data from stable cell 
populations.  (Figs. 3e,f) show mean + SD of triplicate treated cultures and p-values from a 
paired T-test. (g) ChIP analysis was performed to determine changes in histone modifications at 
the 5’LTR in cells expressing the small RNA aspro5.  A reduction of H3K27me3 and H3K9me2 
at the 5’LTR was observed in ACH2 cells transduced with a lentiviral vector expressing aspro5. 
For (Fig. 3g) enrichment at the 5’LTR was determined by qPCR with primer set 3, and n = 4 
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Figure 4 Epigenetic-based mechanism of the HIV-expressed antisense lncRNA-mediated viral 
gene regulation. (a) IFN induction was assessed by measuring IFN-β mRNA concentration in 
total RNA extracted from cells expressing as154 or aspro5 and cells treated with poly (I:C)
which served as a positive control (b) DNMT3a interacts with the HIV-1 expressed antisense 
ncRNA.  Immunoprecipitation of DNMT3a followed by directional RT with RT primer 4, a 
primer within the LTR and specific for the antisense ncRNA, and then PCR with primer set 3,
reveals interactions between DNMT3a and the HIV-1 expressed antisense ncRNA in ACH2 
cells. (c) Localization of the HIV antisense ncRNA to the 5’LTR. A biotin pulldown was 
performed in cells transfected with two synthetic biotinylated fragments of the HIV antisense 
lncRNA, followed by qPCR of the DNA co-precipitated with the biotinylated RNA using LTR-
specific primer set 3.  A synthetic biotinylated antisense ncRNA fragment containing 5’LTR and 
Gag elements binds directly to the HIV 5’LTR in ACH2 cells whereas the control lambda and an 
antisense ncRNA fragment containing Nef and 3’ LTR content does not. (d) Localization of the 
ncRNA-DNMT3a complex to the 5’LTR. A ChIP assay for DNMT3a was performed in cells 
transfected with a T7-transcribed biotinylated HIV asRNA fragment followed by a biotin 
pulldown on the ChIP eluates. DNMT3a and the HIV antisense ncRNA appear to interact with 
each other and both localize to the 5’LTR. (e) The HIV antisense ncRNA guides DNMT3a 
localization to the 5’LTR. A ChIP of DNMT3a shows that DNMT3a localization to the 
5’LTR/promoter is reduced in lentiviral transduced ACH2 cells stably expressing small asRNAs
targeted to the HIV-expressed lncRNA compared to cells transduced with an empty vector
(Control). (f) ChIP analysis of EZH2 at the 5’LTR and (g) ChIP analysis of HDAC1 at the 
5’LTR in lentiviral transduced ACH2 cells stably expressing the inhibitory small RNAs as154 
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these chromatin modifying proteins at the viral promoter when the HIV antisense lncRNA is 
inhibited. (h) The effects of a combination of 5-AC and TSA treatment (Treated) on aspro5 
mediated activation. Stably transduced Jurkat cells were infected with either HIV-1 HX10 or 
NL4-3 and treated with both 5-AC and TSA and HIV gene expression determined 72 hours after 
initial drug treatment. (Figs. 4c,d,e,h) show triplicate treated cells as mean + SD and p-values 
from a paired T-test. (Figs. 4f,g) show the mean + SEM of n=4 ChIP samples and p-values from 
a paired T-test.
Figure 5 Effects of aspro5 on latent viral replication in an ex vivo primary memory CD4+ T 
cell-based latency model [24, 25].  Cells were monitored for viral replication at different time 
points over 12 days and the effects of the aspro5 small asRNA were compared to an empty 
vector control.
Figure 6 Model for HIV-encoded antisense lncRNA mediated regulation of viral transcription.  
(a) A long non-coding RNA (lncRNA) antisense to the viral genome is transcribed from a 
putative promoter within the nef gene.  (b) The lncRNA recruits DNMT3a and possibly other 
chromatin remodeling proteins (Enhancer of Zeste 2 (EZH2), Histone deacetylase 1 (HDAC-1), 
G9a) and (c) guides these proteins to the viral promoter (5’LTR).  (d) The localization of the 
chromatin remodeling complex at the 5’LTR results in the formation of heterochromatin which 
is characterized by H3K9 dimethylation, H3K27 trimethylation and histone deacetylation.  This 
alteration of the chromatin state at the viral promoter leads to transcriptional shutdown and an 
epigenetically silenced virus.  (e) The HIV-encoded lncRNA may be inhibited by small single 
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gene silencing, or by small RNAs targeted to the ncRNA transcript via post-transcriptional gene 
silencing (shown).  (f) The inhibition of the antisense lncRNA by small RNAs prevents the 
recruitment of chromatin remodeling proteins to the viral promoter (5’LTR). (g) The viral 
promoter remains in a euchromatin state, free of silent state epigenetic marks and 
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Table 1 Proteins found by Mass-spec analysis to be associated with DNMT3a and the HIV expressed antisense non-coding 
RNA at the HIV LTR/promoter.






1 Cluster of Histone H2A.V OS=Homo sapiens GN=H2AFV PE=1 SV=3 
(H2AV_HUMAN)*
H2AV_HUMAN 14 kDa 15% 2
2 Cluster of Histone H1.3 OS=Homo sapiens GN=HIST1H1D PE=1 SV=2 
(H13_HUMAN)*
H13_HUMAN 22 kDa 38% 17
3 Nucleolin OS=Homo sapiens GN=NCL PE=1 SV=3 NUCL_HUMAN 77 kDa 6.80% 5
4 Cluster of Tropomyosin alpha-4 chain OS=Homo sapiens GN=TPM4 PE=1 
SV=3 (TPM4_HUMAN)*
TPM4_HUMAN 29 kDa 21% 9
5 Cluster of Histone H2B type 1-C/E/F/G/I OS=Homo sapiens GN=HIST1H2BC 
PE=1 SV=4 (H2B1C_HUMAN)
H2B1C_HUMAN 14 kDa 36% 4
6 Histone H1.5 OS=Homo sapiens GN=HIST1H1B PE=1 SV=3 H15_HUMAN 23 kDa 19% 6
7 Nucleophosmin OS=Homo sapiens GN=NPM1 PE=1 SV=2 NPM_HUMAN 33 kDa 19% 4
8 High mobility group protein B2 OS=Homo sapiens GN=HMGB2 PE=1 SV=2 HMGB2_HUMAN 24 kDa 19% 5
9 60S ribosomal protein L23a OS=Homo sapiens GN=RPL23A PE=1 SV=1 RL23A_HUMAN 18 kDa 22% 4
10 Ribosome-binding protein 1 OS=Homo sapiens GN=RRBP1 PE=1 SV=4 RRBP1_HUMAN 152 kDa 1.40% 2
11 Non-histone chromosomal protein HMG-14 OS=Homo sapiens GN=HMGN1 
PE=1 SV=3
HMGN1_HUMAN 11 kDa 22% 3
12 High mobility group protein HMG-I/HMG-Y OS=Homo sapiens GN=HMGA1 
PE=1 SV=3
HMGA1_HUMAN 12 kDa 22% 2
13 THO complex subunit 4 OS=Homo sapiens GN=ALYREF PE=1 SV=3 THOC4_HUMAN 27 kDa 15% 2
14 Plasminogen activator inhibitor 1 RNA-binding protein OS=Homo sapiens 
GN=SERBP1 PE=1 SV=2
PAIRB_HUMAN 45 kDa 6.60% 2
15 High mobility group protein B1 OS=Homo sapiens GN=HMGB1 PE=1 SV=3 HMGB1_HUMAN 25 kDa 7.00% 2
16 Cluster of Metallothionein-1G OS=Homo sapiens GN=MT1G PE=1 SV=2 
(MT1G_HUMAN)*
MT1G_HUMAN 6 kDa 32% 2
17 Serine/arginine-rich splicing factor 2 OS=Homo sapiens GN=SRSF2 PE=1 SV=4 SRSF2_HUMAN 25 kDa 11% 2
18 60S acidic ribosomal protein P2 OS=Homo sapiens GN=RPLP2 PE=1 SV=1 RLA2_HUMAN 12 kDa 22% 2
19 Heterogeneous nuclear ribonucleoprotein A/B OS=Homo sapiens 
GN=HNRNPAB PE=1 SV=2
ROAA_HUMAN 36 kDa 6.90% 2
20 Cellular nucleic acid-binding protein OS=Homo sapiens GN=CNBP PE=1 SV=1 CNBP_HUMAN 19 kDa 10% 2
21 Putative tropomyosin alpha-3 chain-like protein OS=Homo sapiens PE=5 SV=2 TPM3L_HUMAN 26 kDa 9.90% 2
* Proteins that contained similar peptides and could not be differentiated based on MS/MS analysis alone were grouped.
